Population (P): Patients diagnosed with LC, regardless of country, region, or race. Intervention (I): Intervention is only MSC treatment. Comparison (C): Regular medication or placebo. Outcomes (O): Primary results: model for end-stage liver disease score (MELD); albumin (ALB); secondary outcomes: alanine aminotransferase (ALT); aspartate aminotransferase (AST); international normalized ratio (INR); total bilirubin (TBIL) hepatocellular carcinoma (HCC) survival rate. Study design (S): Only RCTs were included in this study